Porcine Toxicology Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
Open Access
- 1 February 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 65 (2) , 256-265
Abstract
Adenoviral vectors are being actively investigated for their potential utility in gene therapy. SCH 58500, a replication-deficient adenoviral vector, carries the normal p53 tumor suppressor gene, which is frequently mutated or absent in several human cancers. To assess the potential toxicity associated with adenoviral use, Yorkshire pigs were dosed by intravenous, intrahepatic, or local routes (subcutaneous and intradermal) to support a variety of potential clinical indications. Porcine cells were shown to support replication of wild-type human adenovirus. The nonlethal and asymptomatic dose in pigs following dosing via the intrahepatic route was greater than 3 × 108 plaque-forming units (pfu)/kg (2.2 × 1011 particles/kg), but less than 2.1 × 109 pfu/kg (1.5 × 1012 particles/kg). By the intravenous route it was 1 × 108 pfu/kg, and by the ip route it was greater than or equal to 3 × 108 pfu/kg. In a multicycle intraperitoneal study in pigs, the high dose of 3 × 108 pfu/kg caused an increased antibody and/or an inflammatory response. By the intravenous route, plaque-forming units were present in most pigs at 5 min postdose, but only in a few at 10 min postdose. No expression was found in gonadal tissue approximately 3 weeks after a single intravenous injection of 3 × 108 pfu/kg. At high intrahepatic doses (about 1.5 × 1012 particles/kg), acute cardiovascular and hemodynamic effects were found, which in subsequent studies were also present at high doses by intravenous administration. Based on these findings, careful evaluation of hemodynamic parameters in patients receiving systemic doses of SCH 58500 is warranted.Keywords
This publication has 16 references indexed in Scilit:
- Recombinant E1-Deleted Adenovirus-Mediated Gene Therapy for Cancer: Efficacy Studies with p53 Tumor Suppressor Gene and Liver Histology in Tumor Xenograft ModelsHuman Gene Therapy, 1998
- Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of CancerHuman Gene Therapy, 1994
- How loops, β sheets, and α helices help us to understand p53Cell, 1994
- Tumor suppressor genesCurrent Opinion in Genetics & Development, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- p53, guardian of the genomeNature, 1992
- Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumoursNature, 1992
- p53 Mutations in Human CancersScience, 1991
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- Genetic Mechanisms of Tumor Suppression by the Human p53 GeneScience, 1990